The Purpose of the Study is to Continue to Provide Pemigatinib to Patients With Advanced Malignancies.

Inclusion Criteria:

1. Currently enrolled and receiving treatment in an Incyte-sponsored clinical study (parent protocol) of pemigatinib as monotherapy or combination therapy.
2. Currently benefiting from and tolerating treatment with pemigatinib, as determined by the investigator.
3. Demonstrated compliance, as assessed by the investigator, with the parent protocol requirements.
4. Willingness and ability to comply with scheduled visits, treatment plans, and any other study procedures.
5. Currently have no evidence of progressive disease, as determined by the investigator, following treatment with pemigatinib as monotherapy or combination therapy.
6. Willingness to avoid pregnancy or fathering children.

Exclusion Criteria:

1. Able to access pemigatinib commercially or outside of a clinical trial.
2. Permanently discontinued from the parent protocol for any reason.

No longer meet the inclusion/exclusion criteria from the parent protocol if still receiving treatment.



3. Women who are pregnant or breastfeeding or participants expecting to conceive or father children within the projected duration of the study.